Aspirin Use and Risk of Colorectal Cancer Among Older Adults.

Abstract:

Importance:Although aspirin is recommended for the prevention of colorectal cancer (CRC) among adults aged 50 to 59 years, recent data from a randomized clinical trial suggest a lack of benefit and even possible harm among older adults. Objective:To examine the association between aspirin use and the risk of incident CRC among older adults. Design, Setting, and Participants:A pooled analysis was conducted of 2 large US cohort studies, the Nurses' Health Study (June 1, 1980-June 30, 2014) and Health Professionals Follow-up Study (January 1, 1986-January 31, 2014). A total of 94 540 participants aged 70 years or older were included and followed up to June 30, 2014, for women or January 31, 2014, for men. Participants with a diagnosis of any cancer, except nonmelanoma skin cancer, or inflammatory bowel disease were excluded. Statistical analyses were conducted from December 2019 to October 2020. Main Outcomes and Measures:Cox proportional hazards models were used to calculate multivariable adjusted hazard ratios (HRs) and 95% CIs for incident CRC. Results:Among the 94 540 participants (mean [SD] age, 76.4 [4.9] years for women, 77.7 [5.6] years for men; 67 223 women [71.1%]; 65 259 White women [97.1%], 24 915 White men [96.0%]) aged 70 years or older, 1431 incident cases of CRC were documented over 996 463 person-years of follow-up. After adjustment for other risk factors, regular use of aspirin was associated with a significantly lower risk of CRC at or after age 70 years compared with nonregular use (HR, 0.80; 95% CI, 0.72-0.90). However, the inverse association was evident only among aspirin users who initiated aspirin use before age 70 years (HR, 0.80; 95% CI, 0.67-0.95). In contrast, initiating aspirin use at or after 70 years was not significantly associated with a lower risk of CRC (HR, 0.92; 95% CI, 0.76-1.11). Conclusions and Relevance:Initiating aspirin at an older age was not associated with a lower risk of CRC in this pooled analysis of 2 cohort studies. In contrast, those who used aspirin before age 70 years and continued into their 70s or later had a reduced risk of CRC.

journal_name

JAMA Oncol

journal_title

JAMA oncology

authors

Guo CG,Ma W,Drew DA,Cao Y,Nguyen LH,Joshi AD,Ng K,Ogino S,Meyerhardt JA,Song M,Leung WK,Giovannucci EL,Chan AT

doi

10.1001/jamaoncol.2020.7338

subject

Has Abstract

pub_date

2021-01-21 00:00:00

eissn

2374-2437

issn

2374-2445

pii

2775175

pub_type

杂志文章
  • Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.

    abstract:Importance:Epidermal growth factor receptor (EGFR) (HER1) signaling depends on ligand binding and dimerization with itself or other HER receptors. We previously showed in a randomized trial that high EGFR ligand expression is predictive of panitumumab benefit in advanced colorectal cancer. Tumor expression of HER3 may ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2017.3168

    authors: Seligmann JF,Hatch AJ,Richman SD,Elliott F,Jacobs B,Brown S,Hurwitz H,Barrett JH,Quirke P,Nixon AB,Seymour MT

    更新日期:2018-04-01 00:00:00

  • Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.

    abstract:Importance:Metastatic colorectal cancer (mCRC) is heterogeneous, and primary tumors arising from different regions of the colon are clinically and molecularly distinct. Objective:To examine the prognostic and predictive value of primary tumor location in patients with RAS wild-type (wt) mCRC treated with first-line fl...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.3797

    authors: Tejpar S,Stintzing S,Ciardiello F,Tabernero J,Van Cutsem E,Beier F,Esser R,Lenz HJ,Heinemann V

    更新日期:2017-02-01 00:00:00

  • Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.

    abstract:IMPORTANCE:E-cadherin (CDH1) is a cancer predisposition gene mutated in families meeting clinically defined hereditary diffuse gastric cancer (HDGC). Reliable estimates of cancer risk and spectrum in germline mutation carriers are essential for management. For families without CDH1 mutations, genetic-based risk stratif...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2014.168

    authors: Hansford S,Kaurah P,Li-Chang H,Woo M,Senz J,Pinheiro H,Schrader KA,Schaeffer DF,Shumansky K,Zogopoulos G,Santos TA,Claro I,Carvalho J,Nielsen C,Padilla S,Lum A,Talhouk A,Baker-Lange K,Richardson S,Lewis I,Lindor N

    更新日期:2015-04-01 00:00:00

  • Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer.

    abstract:Importance:Breast cancer risk and comorbidities increase with age. Data are lacking on the association of adjuvant chemotherapy with survival in elderly patients with multiple comorbidities and node-positive breast cancer. Objective:To examine the association of chemotherapy with survival in elderly patients with mult...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2388

    authors: Tamirisa N,Lin H,Shen Y,Shaitelman SF,Sri Karuturi M,Giordano SH,Babiera G,Bedrosian I

    更新日期:2020-10-01 00:00:00

  • Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.

    abstract:Importance:Within 10 years after breast cancer diagnosis, roughly 5% of patients develop contralateral breast cancer (CBC). Randomized trials have found that therapy including tamoxifen citrate and aromatase inhibitors (AIs) reduces CBC risk. But little is known about the magnitude and duration of protective associatio...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.3340

    authors: Gierach GL,Curtis RE,Pfeiffer RM,Mullooly M,Ntowe EA,Hoover RN,Nyante SJ,Feigelson HS,Glass AG,Berrington de Gonzalez A

    更新日期:2017-02-09 00:00:00

  • Association of a Bundled-Payment Program With Cost and Outcomes in Full-Cycle Breast Cancer Care.

    abstract:Importance:Value-driven payment system reform is a potential tool for aligning economic incentives with the improvement of quality and efficiency of health care and containment of cost. Such a payment system has not been researched satisfactorily in full-cycle cancer care. Objective:To examine the association of outco...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.4549

    authors: Wang CJ,Cheng SH,Wu JY,Lin YP,Kao WH,Lin CL,Chen YJ,Tsai SL,Kao FY,Huang AT

    更新日期:2017-03-01 00:00:00

  • Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.

    abstract:Importance:The role of epidermal growth factor receptor (EGFR) inhibition in chemoradiation strategies in the nonoperative treatment of patients with esophageal cancer remains uncertain. Objective:To evaluate the benefit of cetuximab added to concurrent chemoradiation therapy for patients undergoing nonoperative treat...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2017.1598

    authors: Suntharalingam M,Winter K,Ilson D,Dicker AP,Kachnic L,Konski A,Chakravarthy AB,Anker CJ,Thakrar H,Horiba N,Dubey A,Greenberger JS,Raben A,Giguere J,Roof K,Videtic G,Pollock J,Safran H,Crane CH

    更新日期:2017-11-01 00:00:00

  • Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men: National Health and Nutrition Examination Survey (NHANES) 2013-2014.

    abstract:Importance:Human papillomavirus (HPV) is a common sexually transmitted infection that is a major cause of noncervical anogenital and oropharyngeal cancers. Prophylactic HPV vaccine is available for primary prevention. However, the population prevalence data for male genital HPV infection is not well known, while the HP...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.6192

    authors: Han JJ,Beltran TH,Song JW,Klaric J,Choi YS

    更新日期:2017-06-01 00:00:00

  • Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis.

    abstract:Importance:The oligometastatic paradigm postulates that patients with a limited number of metastases can be treated with ablative local therapy to each site of disease with curative intent. Stereotactic ablative radiotherapy (SABR) is a radiation technique that has become widely used in this setting. However, prospecti...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.6146

    authors: Lehrer EJ,Singh R,Wang M,Chinchilli VM,Trifiletti DM,Ost P,Siva S,Meng MB,Tchelebi L,Zaorsky NG

    更新日期:2021-01-01 00:00:00

  • Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

    abstract:Importance:In clinical practice, patients with primary metastatic renal cell carcinoma (mRCC) have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the optimal sequence of surgery and systemic therapy is unknown. Objective:To examine whether a period of sunitinib therapy before CN improves...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2018.5543

    authors: Bex A,Mulders P,Jewett M,Wagstaff J,van Thienen JV,Blank CU,van Velthoven R,Del Pilar Laguna M,Wood L,van Melick HHE,Aarts MJ,Lattouf JB,Powles T,de Jong Md PhD IJ,Rottey S,Tombal B,Marreaud S,Collette S,Collette L,

    更新日期:2019-02-01 00:00:00

  • Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma.

    abstract:Importance:The risk stratification of adrenocortical carcinoma (ACC) based on tumor proliferation index and stage is limited. Adjuvant therapy after surgery is recommended for most patients. Pan-genomic studies have identified distinct molecular groups closely associated with outcome. Objective:To compare the molecula...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2019.1558

    authors: Assié G,Jouinot A,Fassnacht M,Libé R,Garinet S,Jacob L,Hamzaoui N,Neou M,Sakat J,de La Villéon B,Perlemoine K,Ragazzon B,Sibony M,Tissier F,Gaujoux S,Dousset B,Sbiera S,Ronchi CL,Kroiss M,Korpershoek E,De Krijger

    更新日期:2019-07-11 00:00:00

  • Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.

    abstract:Importance:Multiple myeloma (MM) is the second most common hematological malignant abnormality. The introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) has greatly improved the overall survival of patients with MM. Prevention and treatment of cardiovascular and thrombotic issues associated wi...

    journal_title:JAMA oncology

    pub_type: 杂志文章,评审

    doi:10.1001/jamaoncol.2016.3350

    authors: Li W,Garcia D,Cornell RF,Gailani D,Laubach J,Maglio ME,Richardson PG,Moslehi J

    更新日期:2017-07-01 00:00:00

  • Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.

    abstract:Importance:Programmed cell death 1 (PD-1) inhibitor-related pneumonitis is a rare but clinically serious and potentially life-threatening adverse event. Little is known about its incidence across different tumor types and treatment regimens. Objective:To compare the incidence of PD-1 inhibitor-related pneumonitis amon...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1001/jamaoncol.2016.2453

    authors: Nishino M,Giobbie-Hurder A,Hatabu H,Ramaiya NH,Hodi FS

    更新日期:2016-12-01 00:00:00

  • Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.

    abstract:Importance:A significant proportion of patients with early-stage triple-negative breast cancer (TNBC) are treated with neoadjuvant chemotherapy. Sequencing of circulating tumor DNA (ctDNA) after surgery, along with enumeration of circulating tumor cells (CTCs), may be used to detect minimal residual disease and assess ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2295

    authors: Radovich M,Jiang G,Hancock BA,Chitambar C,Nanda R,Falkson C,Lynce FC,Gallagher C,Isaacs C,Blaya M,Paplomata E,Walling R,Daily K,Mahtani R,Thompson MA,Graham R,Cooper ME,Pavlick DC,Albacker LA,Gregg J,Solzak JP,C

    更新日期:2020-09-01 00:00:00

  • Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A Review.

    abstract:Importance:Checkpoint blockade therapy targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathways (PD-1/PD-L1) have achieved success in treating a number of malignancies. However, only a subset of patients responds to these therapies, and optimization of patient sele...

    journal_title:JAMA oncology

    pub_type: 杂志文章,评审

    doi:10.1001/jamaoncol.2016.2214

    authors: Dijkstra KK,Voabil P,Schumacher TN,Voest EE

    更新日期:2016-11-01 00:00:00

  • Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.

    abstract:Importance:The value of platinum-based adjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) remains controversial, as does whether BRCA1 and BRCA2 (BRCA1/2) germline variants are associated with platinum treatment sensitivity. Objective:To compare 6 cycles of paclitaxel plus carboplatin (PCb) wi...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2965

    authors: Yu KD,Ye FG,He M,Fan L,Ma D,Mo M,Wu J,Liu GY,Di GH,Zeng XH,He PQ,Wu KJ,Hou YF,Wang J,Wang C,Zhuang ZG,Song CG,Lin XY,Toss A,Ricci F,Shen ZZ,Shao ZM

    更新日期:2020-09-01 00:00:00

  • Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.

    abstract:Importance:To date, the benefit of genome-driven cancer therapy has not been quantified. Objective:We sought to estimate the annual percentage of patients in the United States with advanced or metastatic cancer who could be eligible for and benefit from US Food and Drug Administration (FDA)-approved genome-driven ther...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.1660

    authors: Marquart J,Chen EY,Prasad V

    更新日期:2018-08-01 00:00:00

  • Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma.

    abstract:Importance:To date, there is no well-defined standard of care for early-stage pediatric Hodgkin lymphoma (HL), which may include chemotherapy alone or combined modality therapy (CMT) with chemotherapy followed by radiotherapy. Although the use of radiotherapy in pediatric HL is decreasing, this strategy remains controv...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.5911

    authors: Jhawar SR,Rivera-Núñez Z,Drachtman R,Cole PD,Hoppe BS,Parikh RR

    更新日期:2019-05-01 00:00:00

  • Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.

    abstract:Importance:Hereditary cancer syndromes infer high cancer risks and require intensive cancer surveillance, yet the prevalence and spectrum of these conditions among unselected patients with early-onset colorectal cancer (CRC) is largely undetermined. Objective:To determine the frequency and spectrum of cancer susceptib...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.5194

    authors: Pearlman R,Frankel WL,Swanson B,Zhao W,Yilmaz A,Miller K,Bacher J,Bigley C,Nelsen L,Goodfellow PJ,Goldberg RM,Paskett E,Shields PG,Freudenheim JL,Stanich PP,Lattimer I,Arnold M,Liyanarachchi S,Kalady M,Heald B,Gre

    更新日期:2017-04-01 00:00:00

  • The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.

    abstract:IMPORTANCE:Time to events, or survival end points, are common end points in randomized clinical trials. They are usually analyzed under the assumption of proportional hazards, and the treatment effect is reported as a hazard ratio, which is neither an intuitive measure nor a meaningful one if the assumption of proporti...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.6359

    authors: Péron J,Roy P,Ozenne B,Roche L,Buyse M

    更新日期:2016-07-01 00:00:00

  • Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT-A Randomized Clinical Trial in Early Breast Cancer.

    abstract:Importance:Conventional adjuvant radiotherapy for breast cancer given daily for several weeks is onerous and expensive. Some patients may be obliged to choose a mastectomy instead, and some may forgo radiotherapy altogether. We proposed a clinical trial to test whether radiotherapy could be safely limited to the tumor ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2020.0249

    authors: Vaidya JS,Bulsara M,Saunders C,Flyger H,Tobias JS,Corica T,Massarut S,Wenz F,Pigorsch S,Alvarado M,Douek M,Eiermann W,Brew-Graves C,Williams N,Potyka I,Roberts N,Bernstein M,Brown D,Sperk E,Laws S,Sütterlin M,Lu

    更新日期:2020-07-01 00:00:00

  • Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.

    abstract:Importance:Low-cost sequencing of multiple genes is increasingly available for cancer risk assessment. Little is known about uptake or outcomes of multiple-gene sequencing after breast cancer diagnosis in community practice. Objective:To examine the effect of multiple-gene sequencing on the experience and treatment ou...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.0644

    authors: Kurian AW,Ward KC,Hamilton AS,Deapen DM,Abrahamse P,Bondarenko I,Li Y,Hawley ST,Morrow M,Jagsi R,Katz SJ

    更新日期:2018-08-01 00:00:00

  • Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer.

    abstract:Importance:Black individuals are underrepresented in cancer clinical trials. Objective:To examine whether Black and White men with prostate cancer differ in their willingness to discuss clinical trials with their physicians and, if so, whether patient-level barriers statistically mediate racial differences. Design, S...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.3697

    authors: Senft N,Hamel LM,Manning MA,Kim S,Penner LA,Moore TF,Carducci MA,Heath EI,Lansey DG,Albrecht TL,Wojda M,Jordan A,Eggly S

    更新日期:2020-09-17 00:00:00

  • Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.

    abstract:Importance:Randomized trials in breast cancer have demonstrated the clinical benefits of adjuvant endocrine therapy (AET) in preventing recurrence and death. The examination of concordance with AET guidelines at a national level as a measure of quality of care is important. Objective:To investigate temporal trends and...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.6380

    authors: Daly B,Olopade OI,Hou N,Yao K,Winchester DJ,Huo D

    更新日期:2017-07-01 00:00:00

  • Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.

    abstract:Importance:Novel intermediate end points may be useful to detect signals of early activity and prioritize new therapies to treat patients with advanced malignant neoplasms, including metastatic non-small cell lung cancer (mNSCLC). Objective:To explore milestone rate, a proposed intermediate end point for immunotherapy...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析

    doi:10.1001/jamaoncol.2017.1029

    authors: Blumenthal GM,Zhang L,Zhang H,Kazandjian D,Khozin S,Tang S,Goldberg K,Sridhara R,Keegan P,Pazdur R

    更新日期:2017-08-10 00:00:00

  • Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.

    abstract:Importance:Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-risk prostate cancer setting. Objective:To assess the benefit of ADT plus docetaxel in patients presenting with rising prostate-specific ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2018.6607

    authors: Oudard S,Latorzeff I,Caty A,Miglianico L,Sevin E,Hardy-Bessard AC,Delva R,Rolland F,Mouret L,Priou F,Beuzeboc P,Gravis G,Linassier C,Gomez P,Voog E,Muracciole X,Abraham C,Banu E,Ferrero JM,Ravaud A,Krakowski I,L

    更新日期:2019-05-01 00:00:00

  • The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials.

    abstract:IMPORTANCE:Positive phase 3 cancer clinical trials are widely hailed, while trials with negative results are often interpreted as scientific failures. We hypothesized that these interpretations would be reflected in the scientific literature. OBJECTIVE:To compare the scientific impact of positive vs negative phase 3 c...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.6487

    authors: Unger JM,Barlow WE,Ramsey SD,LeBlanc M,Blanke CD,Hershman DL

    更新日期:2016-07-01 00:00:00

  • Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer.

    abstract:Importance:Sarcopenia (low muscle mass), poor muscle quality (low muscle radiodensity), and excess adiposity derived from computed tomography (CT) has been related to higher mortality in patients with metastatic breast cancer, but the association with prognosis in patients with nonmetastatic breast cancer is unknown. ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.0137

    authors: Caan BJ,Cespedes Feliciano EM,Prado CM,Alexeeff S,Kroenke CH,Bradshaw P,Quesenberry CP,Weltzien EK,Castillo AL,Olobatuyi TA,Chen WY

    更新日期:2018-06-01 00:00:00

  • Time to Surgery and Breast Cancer Survival in the United States.

    abstract:IMPORTANCE:Time to surgery (TTS) is of concern to patients and clinicians, but controversy surrounds its effect on breast cancer survival. There remains little national data evaluating the association. OBJECTIVE:To investigate the relationship between the time from diagnosis to breast cancer surgery and survival, usin...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.4508

    authors: Bleicher RJ,Ruth K,Sigurdson ER,Beck JR,Ross E,Wong YN,Patel SA,Boraas M,Chang EI,Topham NS,Egleston BL

    更新日期:2016-03-01 00:00:00

  • Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.

    abstract:Importance:Remarkable progress has occurred in understanding the pathophysiology and in developing improved personalized therapies in adult acute lymphoblastic leukemia (ALL). Observations:We searched MEDLINE (1990-2018), the American Society of Clinical Oncology, and American Society of Hematology websites (2010-2018...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.1915

    authors: Jabbour E,Pui CH,Kantarjian H

    更新日期:2018-10-01 00:00:00